ReviewSensors (Basel, Switzerland)2021
Plasmonic Nanoparticles as Optical Sensing Probes for the Detection of Alzheimer's Disease.
Review in Sensors (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 55 citations in OpenAlex.
- Blood-based multiplex nanobiosensing of Alzheimer's disease biomarkers: from nanoengineered ınterfaces to clinical translation.Metabolic brain disease · 2026Review
- Progress in Optical Methods for the Detection of Two Core Blood Biomarkers of Alzheimer's Disease: Amyloid-Beta and Tau Proteins.Biosensors · 2026Review
- A Degradable Nanosystem Based on Small Gold Nanoparticles and Albumin for Amyloid Aggregation Inhibition.Pharmaceutics · 2026Article
- Nano-based spectroscopic approaches for early diagnosis of Alzheimer's disease: critical insights into amyloid-β and tau biomarker biology and detection tools.Biophysical reviews · 2026Review
- Utilizing nanotechnology to diagnose and treat central nervous system disorders.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Review
- Attenuation of blood-brain barrier dysfunction by functionalized gold nanoparticles against amyloid-β peptide in an Alzheimer's disease-on-a-chip model.Materials today. Bio · 2025Article
- A Sandwich-Type Impedimetric Immunosensor for the Detection of Tau-441 Biomarker.Bioengineering (Basel, Switzerland) · 2025Article
- Stimuli-Responsive Nanomedicines for the Treatment of Non-cancer Related Inflammatory Diseases.ACS nano · 2025Review
- Tau- and α-synuclein-targeted gold nanoparticles: applications, opportunities, and future outlooks in the diagnosis and therapy of neurodegenerative diseases.Journal of nanobiotechnology · 2024Review
- Recent Developments of Hybrid Fluorescence Techniques: Advances in Amyloid Detection Methods.Current protein & peptide science · 2024Review
- Review
- Near-Infrared Perfect Absorption and Refractive Index Sensing Enabled by Split Ring Nanostructures.Nanomaterials (Basel, Switzerland) · 2023Article
- Fluorescent Sensing Platforms for Detecting and Imaging the Biomarkers of Alzheimer's Disease.Biosensors · 2023Review
- Challenges and opportunities for SERS in the infrared: materials and methods.Nanoscale advances · 2023Review
- Gold and silver nanoparticles in Alzheimer's and Parkinson's diagnostics and treatments.Ibrain · 2023Review
- Ultrasensitive and real-time optical detection of cellular oxidative stress using graphene-covered tunable plasmonic interfaces.Nano convergence · 2022Article
- From Research to Diagnostic Application of Raman Spectroscopy in Neurosciences: Past and Perspectives.Free neuropathology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Alzheimer's disease (AD), considered a common type of dementia, is mainly characterized by a progressive loss of memory and cognitive functions. Although its cause is multifactorial, it has been associated with the accumulation of toxic aggregates of the amyloid-β peptide (Aβ) and neurofibrillary tangles (NFTs) of tau protein. At present, the development of highly sensitive, high cost-effective, and non-invasive diagnostic tools for AD remains a challenge. In the last decades, nanomaterials have emerged as an interesting and useful tool in nanomedicine for diagnostics and therapy. In particular, plasmonic nanoparticles are well-known to display unique optical properties derived from their localized surface plasmon resonance (LSPR), allowing their use as transducers in various sensing configurations and enhancing detection sensitivity. Herein, this review focuses on current advances in in vitro sensing techniques such as Surface-enhanced Raman scattering (SERS), Surface-enhanced fluorescence (SEF), colorimetric, and LSPR using plasmonic nanoparticles for improving the sensitivity in the detection of main biomarkers related to AD in body fluids. Additionally, we refer to the use of plasmonic nanoparticles for in vivo imaging studies in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.